Dysregulated signaling promotes the expression of inhibitory receptors, such as PD-L1, on tumor cells and tumor-associated macrophages (TAMs), and upregulates suppressor of cytokine signaling 2 (SOCS2) in DCs, contributing to TME reprogramming [180–183]. The gene discussed is SOCS2; the disease is neoplasm.